Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances

Ionis Pharmaceuticals (IONS) Long-Term Debt Issuances (2017 - 2024)

Ionis Pharmaceuticals (IONS) has disclosed Long-Term Debt Issuances for 4 consecutive years, with $44.5 million as the latest value for Q4 2024.

For Q4 2024, Long-Term Debt Issuances rose 151.27% year-over-year to $44.5 million; the TTM value through Dec 2024 reached -$42.3 million, down 112.68%, while the annual FY2025 figure was $770.0 million, N/A changed from the prior year.
Long-Term Debt Issuances hit $44.5 million in Q4 2024 for Ionis Pharmaceuticals, up from -$86.8 million in the prior quarter.
Across five years, Long-Term Debt Issuances topped out at $420.4 million in Q2 2023 and bottomed at -$313.5 million in Q4 2021.
Average Long-Term Debt Issuances over 3 years is $16.2 million, with a median of -$21.2 million recorded in 2023.
On a YoY basis, Long-Term Debt Issuances climbed as much as 151.27% in 2024 and fell as far as 151.27% in 2024.
Ionis Pharmaceuticals' Long-Term Debt Issuances stood at -$313.5 million in 2021, then surged by 72.31% to -$86.8 million in 2023, then skyrocketed by 151.27% to $44.5 million in 2024.
According to Business Quant data, Long-Term Debt Issuances over the past three periods came in at $44.5 million, -$86.8 million, and $420.4 million for Q4 2024, Q4 2023, and Q2 2023 respectively.